EVOLVE-105 / EvolveImmune Therap - LARVOL DELTA

EVOLVE-105, a differentiated CD20-targeted CD2 co-stimulatory T cell engager engineered for the treatment of B cell malignancies (AACR 2024) - "Despite the recent approvals of CD20-targeted CD3 bispecific molecules in follicular lymphoma (Lunsumio™, mosunetuzumab) and diffuse large B cell lymphoma (Columvi™, glofitamab; and Epkinly™, epcoritamab), significant opportunities to improve patient outcomes in these indications remain...EVOLVE-105 also displays superior potency compared to the CD20xCD3 clinical benchmarks mosunetuzumab, epcoritamab, and odronextamab...EVOLVE-105 demonstrates favorable biophysical properties conducive to its development as intravenous and subcutaneous formulations. The emerging profile of EVOLVE-105 suggests its potential as a differentiated CD20-targeted immunotherapy capable of providing superior, more durable tumor control with a preferred cytokine release profile, compared to current CD20-targeted T cell engager therapies."

Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • IFNG • IL6 • TNFA

EvolveImmune Therapeutics Presents New Preclinical Data Demonstrating Improved Anti-Tumor Potential of Novel Costimulatory T Cell Engager Platform at Festival of Biologics Immunotherapy World Congress (GlobeNewswire) - "EvolveImmune Therapeutics...announced that new preclinical data on EVOLVE™, the company’s novel costimulatory T cell engager platform, were featured in an oral presentation at the Festival of Biologics Immunotherapy World Congress. The presentation highlighted the potential of the company’s innovative integrated CD2 costimulatory strategy to overcome treatment limitations of current immunotherapies. Additionally, the company disclosed the first data for EVOLVE-105, its best-in-class CD20xCD3 multispecific T cell engager that also selectively mediates CD2 costimulation."

New molecule • Preclinical • Hematological Malignancies • Oncology